• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Lotus Tissue Repair

edit

Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions.

Milestones

edit

• 
  Lotus Tissue Repair received $26M in Series A funding. (6/30/11)
  Posted 6/30/11 at 3:54am via businessinsider.com

Videos

Screenshots

edit

Above: Lotus Tissue Repair
Uploaded: 6/30/11

Sources

1. Lotus Tissue Repair, Inc. Secures $26 Million Series A Financing to Develop First-in-Class Protein Replacement Therapy for Dystrophic Epidermolysis Bullosa (financial.businessinsider.com) [edit]